Musk Claims Tesla Optimus Develops Highly Dexterous Hands for Precision Medical Procedures and Complex Surgeries
Musk stated that the Tesla Optimus is developing highly dexterous hands for executing precision medical operations and complex surgeries, rather than just for factory handling.
In a conversation with investor Ron Baron, he mentioned that the next generation of Optimus will have about 50 actuators in each hand and forearm; a total of about 100 actuators for both hands. The actuators, composed of motors, gear mechanisms, and power electronics, are the core hardware units enabling force control, joint movement, and tactile feedback in robotic hands.
Musk emphasized the difficulty of the "hand" in humanoid robot development: everyday actions such as picking up a screwdriver, turning a wrench, threading a needle, or playing guitar rely on the sensitivity, precision, and freedom of human hands. He stated that for robots to accomplish dexterous tasks, their hand capabilities must reach a level of perception and movement similar to that of human hands.
He further claimed that Optimus should achieve "superhuman-level" precision in the future, capable of handling highly complex medical procedures and even performing tasks that humans cannot complete due to operational difficulties; this is Musk's goal description for future product capabilities, not a validated ability that has entered clinical use.
Musk provided a medical rationale: top surgical capabilities are constrained by training cycles, workforce numbers, physical loads, and geographic distribution. While money can increase doctors' salaries, it cannot quickly replicate top operators. If robots can stably replicate actions, visual and force control capabilities, a single expert-level operating system can be expanded to more regions through mass-produced robotic carriers.
In market mechanisms, hospitals and medical service networks are potential buyers. They are not purchasing a general humanoid robot, but rather a regulatory-approved automated operating system that can reduce variability in specific surgeries and improve operating room utilization. Beneficiaries will include surgical robots, precision gear reducers, torque sensors, machine vision, medical-grade software, clinical data, and liability insurance providers; high-cost manual surgery supply, healthcare institutions dependent on surgical volume, and equipment manufacturers lacking robotic integration capabilities will face pressure. The true variables determining capital flow are clinical trials, indication approvals, fault liability, training, and payer reimbursements, rather than the number of actuators.
Source: Public Information
ABAB AI Insight
Tesla's humanoid robot roadmap initially served the manufacturing industry: the Tesla Bot concept was unveiled at AI Day in 2021, followed by continuous demonstrations of Optimus performing material handling, sorting, and simple assembly tasks in factory environments. Musk now positions surgery as the ultimate scenario for hand development because industrial tasks can tolerate slower speeds, repetitive stations, and controlled environments, while surgery demands millimeter-level or higher precision, real-time visual understanding, flexible tissue handling, bleeding and complication management, and auditable human-machine responsibility boundaries. The two are not of the same technical difficulty level.
In terms of capital pathways, Tesla is transferring the motor control, visual neural networks, embedded computing, actuator manufacturing, and scaled supply chains accumulated from automotive manufacturing to Optimus. The 50-actuator hand represents a shift in capital expenditure from large model training and complete assembly to high-performance micro motors, reducers, sensors, thermal management, reliability verification, and data collection; if the robot first achieves paid work in factories, manufacturing revenue and internal usage data can fund and provide training scenarios for subsequent more expensive medical-grade validation.
Historically, Intuitive Surgical's da Vinci system has proven that surgical robots can establish a high-margin ecosystem of devices, consumables, and training, but it centers on surgeon control, not autonomous replacement of doctors. Musk proposes a leap from "master-slave teleoperation" to "replicable autonomous expert operation," with its technology and regulatory thresholds closer to autonomous driving: systems must maintain safety in a large number of rare boundary cases, while the acceptable error rate for medical accidents is usually far lower than for consumer or factory-grade robots. At this stage, Optimus remains an early-stage general-purpose robot project and has not yet entered clinical surgical deployment.
Essentially, this is about technological substitution: the most scarce resource in healthcare is not the budget for building or equipment procurement, but the human operational capability that has undergone long-term training and can make nuanced continuous actions and clinical judgments in high-risk scenarios. If robots can break down this capability into trainable software, mass-producible hardware, and replicable clinical processes, supply constraints will shift from "how many doctors to train" to "how many validated systems can be deployed." However, substitution will first occur in clearly defined surgical steps with standardized actions and verifiable imaging results, rather than a comprehensive replacement of surgeons in the short term.
ABAB News · Cognitive Laws
Scarcity is not a price issue, but a replication speed issue
Machines replace hands, but systems determine who can replace responsibility
Automation first consumes repetitive actions, then approaches complex judgments